원문 보기
So friends, in today's video we will talk about Mangalam Drugs and Organic Limited, which has been seen in the last working days that with a rise of 5%, the share price of the company is ₹30, it is being seen around 30, friends, when was the company listed in NSCBSE, you can see that the company was established in 1977, Mangalam Drugs, as you can see, is related to pharmaceutical, if we look at its website, what is its market cap ?
So it is worth Rs 48 crores. Talking about the current price, it is ₹30. If we talk about the high of the company, it has gone up to ₹130. Talking about the company's low, friends, it is seen trading around ₹22.70, which means the company's low position. If we talk about PE stock then it is not given.
Talking about book value, it is seen around ₹80.50. Talking about dividend, the company was not able to pay it. But if we talk about ROCE, then ROCE of 8% was seen and if we talk about ROE, then ₹4.7% was seen, friends. Whereas if we talk about face value, then ₹10 face value has been seen in it, friends.
But when you look at the long term chart of Mangalam Drugs and Organic Limited, it may appear very dangerous to you, friends. Talking about the company, you can see here the proxies and ks which is the stock is trading at 0.38 times its book value. As you have already seen, its book value is ₹80.50 and the price of the company is ₹30.
Meaning it is trading at less than half of its book value. Meaning it is trading 0.4 times. Company working capital requirement has reduced from 22.9 working days to 13.4 days. Ok, that's a good thing. If we talk about the company, then the company is giving low interest coverage ratio. It's too low.
The company has delivered a poor sales growth. The sales growth of the company is also very slow. If we talk about the last 5 years, only 2.42% growth was seen in it. Friends, if we look at the return on equity of the company, it is running in negative. Last 3 years. If we look at the liability of the company, it is Rs 34.6 crore.
The promoters' 34.6% stake is mortgaged. The pledge is kept. You can see here, this is the cash of this company, friends. Now let's move on to its pair companies, you are already seeing that like Torrents Pharma, SPL, Sun Pharma, Dr. Red LB, Lupin, Zydus Life L Science, Mangalam Drugs, many big companies are its pair companies friends.
If we talk about its quarterly result, then you can see in the sales as you can see in 2024, its December quarter on quarter decline is being seen in it, friends, here in the sales and if we talk about yearly, then here we can see that you can see the yearly sales increasing gradually, 2699 269 228, till here there was a decline.
Then after here you can see that the company has 282 sales in March 2020. 380 in March 2021, 450 in March 2022, after that again a downward trend was seen in it. Friends, it is being seen continuously down. So there is no increase in sales. Here, if we talk about its low profit, then look at the profit, how good it was before Rs 20 crore.
6 crore 16 crore 22 crore then you can see it here also. Then it is going into minus also. In this current situation, what you see is -19 crores, which means that the company is not able to generate profit somewhere because its sales growth is very slow. If we talk about compound end sales growth, then it has given 4% in 10 years, 2% in 5 years and -1% in 3 years.
Whereas if we talk about compounded profit growth, firstly 1% in 10 years, -4% in 5 years, -30% in 3 years and -36% in current year. If we look at the stock price CAGR, then -19% in 10 years, -26% in 5 years, -39% in 3 years, 75% in 1 year. If we talk about return on equity, then 9% in 10 years, 7% in 5 years, 0% in 3 years and 5% in the last year.
Talking about the balance sheet, the company has a reserve of Rs 112 crore and if we talk about borrowing, you see 95 borrowings and 112 reserves, which means the borrowing and the company's reserves are both equal. Mann can say that we can assume that if it exhausts its entire reserve then its borrowing will be equal.
So if the company does not have cash flow then there will be problems in doing business. So somewhere we can see that more negative impact was seen on the company. Friends, less positive things were seen. So if you look at its share holding pattern, you can see that here the promoters' holding is 50%.
Now even in 50%, you can see that 60% of that 50% is pledged, which means the company has 20% of its shares left and the rest are pledged shares. Talking about FI, you can see 0.11 in it, whereas if you look at the public share, you can see 49.57%, friends. So if we talk about this company overall, it is not that big, but if we look at the recent times, Vijay Keria has made a huge investment in it, friends, so because of this, the 5% rise that you have seen, it may also be because of Vijay Keria's investment, that is why we are seeing this rise, friends, so do not get trapped in such traps, friends, if you like this video, then do like, subscribe and share our channel, thank you for today.
Comments 0